Načítá se...
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
BACKGROUND: The phase ½ hemophilia B clinical trial (AMT-060) demonstrated stable endogenous FIX levels after 3.5 years (mean FIX activity between 5.1% and 7.5%) with continued reductions in annualized bleeds to near zero with the higher dose, and a 78–96% reduction by year in exogenous FIX use. OBJ...
Uloženo v:
| Vydáno v: | Patient Prefer Adherence |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7184858/ https://ncbi.nlm.nih.gov/pubmed/32368018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S239810 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|